Read the latest Quest newsletter

QUEST is a FREE newsletter published three times a year by the Urological Research Foundation. It informs readers of the latest advances in urologic research, especially prostate cancer treatment.

Please click here to subscribe to QUEST.

QUEST is a free newsletter, but we appreciate your support in helping the URF bring this publication to its readers.

Risk of Second Cancers in Prostate Cancer Survivors

The current 10-year relative survival rate for men diagnosed with prostate cancer is 99.7%. This long life expectancy could expose patients to the possibility of developing second primary cancers. In 2011, Dr. Catalona and his research team found that the…

Read More

FDA Update on Testosterone Replacement Therapy

In March, the U.S. Food and Drug Administration (FDA) determined that prescription testosterone therapy is approved only for men who have low testosterone levels caused by certain medical conditions, not men with agerelated low testosterone. “The benefit and safety of…

Read More

Health Policy and Advocacy for Urology

The winter 2014 issue of QUEST included a Q&A with Dr. Chris Gonzalez, a specialist in reconstructive pelvic surgery. In addition to his surgical responsibilities, Dr. Gonzalez works with the American Urological Association (AUA) as vice chairman of health policy,…

Read More

Using PHI to Reduce Unnecessary Biopsies

Dr. Catalona and other researchers investigated whether the Prostate Health Index (phi) test improved specificity for detecting clinically significant prostate cancer to help reduce prostate cancer overdiagnosis. The team compared the performance of PSA, percent-free PSA, [-2]proPSA and phi in…

Read More

Screening for Lynch Syndrome Genetic Mutations

Lynch syndrome is a hereditary disorder caused by germline mutations in the DNA mismatch repair (MMR) genes MLH1, MSH2, MSH6 and PMS2. Normally, MMR genes repair DNA damage generated during DNA replication. When these genes are mutated, they may fail…

Read More

Subscribe to Quest